ABSTRACT To curb the pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), multiple platforms have been employed toward a safe and highly effective vaccine. Here, we develop a novel cell-based vaccine candidate, namely K562-S, by utilizing human cell K562 as a cellular carrier to display Spike (S) protein of SARS-CoV-2 on the membrane. Analogous to the traditional inactivated vaccine, K562-S cells can be propagated to a large scale by culturing and completely lose their viability after exposure to X-ray irradiation or formalin. We in turn demonstrated high immunogenicity of formalin-inactivated K562-S vaccine in both mouse and non-human primates and its protective efficacy in mice. In mice, immunization with inactivated K562-S vaccines can elicit potent neutralizing antibody (nAb) responses persisting longer than 5 months. We consequently showed in a hACE2 mouse model of SARS-CoV-2 infection that a two-shot vaccination with adjuvanted K562-S rendered greater than 3 log reduction in viral lung load and concomitant ameliorated lung pathology. Of importance, the administration of the same regimen in non-human primates was able to induce a neutralizing antibody titer averaging three-fold higher relative to human convalescent serum. These results together support the promise of K562-based, S-protein-expressing vaccines as a novel vaccination approach against SARS-CoV-2. Importantly, with a powerful capacity to carry external genes for cell-based vectors, this platform could rapidly generate two- and multiple-valent vaccines by incorporating SARS-CoV-2 mutants, SARS-CoV, or MERS-CoV.
【저자키워드】 neutralizing antibody, SARS-CoV-2, protection, mouse model, cell-based vaccines, K562-S, non-human primate model, 【초록키워드】 COVID-19, coronavirus disease, neutralizing antibody, Coronavirus disease 2019, Efficacy, Vaccine, coronavirus, vaccination, pandemic, spike, SARS-CoV, SARS-COV-2 infection, lung, severe acute respiratory syndrome Coronavirus, MERS-CoV, immunization, hACE2, X-ray, Protein, Viral, Inactivated vaccine, mice, non-human primates, viability, response, Antibody titer, vaccine candidate, membrane, respiratory, convalescent serum, non-human primate, platform, inactivated, NAb, Neutralizing antibody titer, Protective, Lung pathology, cellular, administration, Log reduction, S-protein, Safe, regimen, exposure to, formalin, Support, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, promise, SARS-CoV-2 mutants, vectors, human cell, external genes, approach, effective, Cell, greater, develop, caused, generate, in viral, demonstrated, elicit, induce, turn, ameliorated, external gene, 【제목키워드】 SARS-CoV-2 vaccine, Neutralizing antibody response, PROTECT, elicit,